Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares OutstandingShares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Atea Pharmaceuticals (AVIR) EBT (2019 - 2026)

Atea Pharmaceuticals' EBT history spans 8 years, with the latest figure at -$45.4 million for Q1 2026.

  • Quarterly EBT fell 33.23% to -$45.4 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was -$175.8 million through Mar 2026, down 26.87% year-over-year, with the annual reading at -$164.5 million for FY2025, 1.76% up from the prior year.
  • EBT came in at -$45.4 million for Q1 2026, up from -$51.6 million in the prior quarter.
  • In the past five years, EBT ranged from a high of -$11.9 million in Q3 2022 to a low of -$62.9 million in Q1 2024.
  • The 5-year median for EBT is -$35.3 million (2023), against an average of -$37.2 million.
  • The largest YoY upside for EBT was 46.14% in 2022 against a maximum downside of 457.19% in 2022.
  • Atea Pharmaceuticals' EBT stood at -$34.3 million in 2022, then dropped by 13.14% to -$38.8 million in 2023, then grew by 14.16% to -$33.3 million in 2024, then tumbled by 54.98% to -$51.6 million in 2025, then increased by 12.09% to -$45.4 million in 2026.
  • Per Business Quant, the three most recent readings for AVIR's EBT are -$45.4 million (Q1 2026), -$51.6 million (Q4 2025), and -$41.9 million (Q3 2025).